PRKAA1 and melanoma: Treatment of B16F10 melanoma cells with the cell-permeable AMPK activator, aminoimidazole-4-carboxamide riboside (AICAR), resulted in the dose-dependent activation of AMPK (Figure 3A) and concomitant suppression of the α-MSH-induced increases in the melanin contents, melanin secretion (Figure 3B), tyrosinase activity (Figure 3C), and expression of melanogenesis-related genes (Figure 3D).